Skip to main content

Table 1 Characteristics of patients with haematological malignancies

From: Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study

Characteristics

Patients (n = 8064)

Sex, n (%)

 Male

4578 (56.8)

 Female

3486 (43.2)

Age, years, median (Q1–Q3)

70 (61–78)

 ≤ 17 years

17 (0.2)

 18–64 years

2624 (32.5)

 65–74 years

2504 (31.0)

 ≥ 75 years

2919 (36.2)

Underlying disease, n (%)

 Hodgkin lymphoma

199 (2.5)

 non-Hodgkin lymphoma

4028 (50.0)

 Multiple myeloma

1153 (14.3)

 Lymphoid leukaemia

551 (6.8)

 Myeloid leukaemia

1224 (15.2)

 Myelodysplastic syndromes

909 (11.3)

CCI, n (%)

 ≤ 2

6394 (79.3)

 3–5

1392 (17.3)

 > 5

278 (3.4)

Follow-up duration, days, median (Q1–Q3)

97 (26–227)

Total LOS, days, median (Q1–Q3)

50 (22–107)

LOS at one hospitalization, days, median (Q1–Q3)

19 (10–30)

Chemotherapy, n (%)

6542 (81.1)

Febrile neutropenia, n (%)

1100 (13.6)

G-CSF, n (%)

4039 (50.1)

Central venous catheter, n (%)

3072 (38.1)

Urinary catheter, n (%)

2109 (26.2)

HSCT, n (%)

 Allogeneic

407 (5.0)

 Autologous

301 (3.7)

 Isolation room, n (%)

2352 (29.2)

 In-hospital mortality, n (%)

1761 (21.8)

  1. CCI Charlson comorbidity index, LOS length of stay, G-CSF Granulocyte-colony stimulating factor, HSCT haematopoietic stem cell transportation